Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Epigenomics' Q1 Revenues Drop 5 Percent

Epigenomics' Q1 Revenues Drop 5 Percent

May 10, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

  2. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  3. Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

    Premium

  4. ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

  5. Inflammatix Receives $1.1M DARPA Award to Develop Predictive COVID-19 Diagnostic

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.